The US Food and Drug Administration (FDA) has rejected United States-based Evolus' application seeking approval of DWP-450 intended to treat glabellar lines (frown lines) in adult patients, it was reported yesterday.
The regulator issued a complete response letter to the company, citing deficiencies regarding chemistry, manufacturing and controls processes. The company stated that that the FDA did not identify any deficiencies associated to clinical or non-clinical matters. The company's CEO, David Moatazedi, stated that the firm expects to respond to the concerns within 90 days.
DWP-450 (prabotulinumtoxinA) is a 900 kilodalton (kDa) purified botulinum toxin type A complex. The product candidate's marketing authorisation application is presently also under review by the European Medicines Agency (EMA).
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval